Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge (Q34437167)

2 August 2017

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge (English)

1 reference

2 August 2017

1 reference

1 reference

0 references

Annie W Lau-Kilby

5

0 references

Joshua C Johnson

object named as

Joshua C Johnson

6

0 references

Anna N. Honko

object named as

Anna N Honko

2

0 references

John R. Mascola

19

object named as

John Mascola

1 reference

2 August 2017

18

Gary J Nabel

1 reference

2 August 2017

7

Lisa Hensley

1 reference

2 August 2017

17

Mario Roederer

1 reference

2 August 2017

22

Richard A Koup

1 reference

2 August 2017

23

Nancy J Sullivan

1 reference

2 August 2017

1

Daphne A Stanley

1 reference

2 August 2017

11

Kathryn E Foulds

1 reference

2 August 2017

Clement Asiedu

3

1 reference

2 August 2017

John C Trefry

4

1 reference

2 August 2017

Virginia Ammendola

8

1 reference

2 August 2017

Adele Abbate

9

1 reference

2 August 2017

Fabiana Grazioli

10

1 reference

2 August 2017

Cheng Cheng

12

1 reference

2 August 2017

Lingshu Wang

13

1 reference

2 August 2017

Mitzi M Donaldson

14

1 reference

2 August 2017

Stefano Colloca

15

1 reference

2 August 2017

Antonella Folgori

16

1 reference

2 August 2017

Alfredo Nicosia

20

1 reference

2 August 2017

Riccardo Cortese

21

1 reference

2 August 2017

language of work or name

English

0 references

publication date

7 September 2014

1 reference

2 August 2017

1 reference

2 August 2017

20

1 reference

2 August 2017

1126-1129

1 reference

2 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.3702

2 August 2017

0 references

cites work

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

21 January 2018

1 reference

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

21 January 2018

1 reference

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

21 January 2018

1 reference

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization

21 January 2018

1 reference

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

21 January 2018

1 reference

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

21 January 2018

1 reference

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

21 January 2018

1 reference

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

21 January 2018

1 reference

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

21 January 2018

1 reference

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

21 January 2018

1 reference

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

21 January 2018

1 reference

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

21 January 2018

1 reference

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

21 January 2018

1 reference

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

21 January 2018

1 reference

T-cell quality in memory and protection: implications for vaccine design

21 January 2018

1 reference

HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha.

21 January 2018

1 reference

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

21 January 2018

1 reference

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

21 January 2018

1 reference

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates

21 January 2018

1 reference

The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.

21 January 2018

1 reference

SPICE: exploration and analysis of post-cytometric complex multivariate datasets

21 January 2018

1 reference

Transcriptional profiling of the circulating immune response to lassa virus in an aerosol model of exposure

21 January 2018

1 reference

Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25194571

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NM.3702

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference